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ABSTRACT
Objective: The objective of the study was to evaluate the effect of luteal phase progesterone supplementation on pregnancy rates in anovulatory 
infertile polycystic ovary women using letrozole with or without gonadotropin as ovulation induction (OI).
Method: A prospective randomized clinical study conducted in the infertility clinic - Al-Yarmouk Teaching Hospital, Baghdad/Iraq from June 2016 
to January 2018. A total of 149 infertile polycystic ovary women who achieved ovulation using letrozole alone or with gonadotropin as OI protocol 
enrolled. Accordingly, the study group divided into two: Group A (letrozole group, no=99) and Group B (letrozole gonadotropin group, no=50). After 
triggering with human Chorionic Gonadotropin, the women in each group were randomly divided into two subgroup women with luteal phase support 
(LPS) and women without. The primary outcome measure was pregnancy rate.
Results: The study shows that pregnancy rate was higher with letrozole group using LPS although the difference did not reach statistical significant 
(p=0.08). After adjustment of possible confounders; patients receiving letrozole with gonadotropin with LPS had significantly higher successful 
pregnancy rate.
Conclusion: Administration of LPS after OI in infertile polycystic ovarian syndrome women may improve pregnancy rate.
Keywords: Gonadotropin, Letrozole, Progesterone, Luteal Phase, Polycystic ovarian syndrome.
INTRODUCTION
Polycystic ovarian syndrome (PCOS) is a principal endocrine system 
disorder affecting women of reproductive age [1]. It is a chronic 
disease and represents a major health and economic burden [2]. It has 
important and various implications, including reproductive, metabolic, 
and psychological features [3]. Diagnosis of PCOS largely depends 
on Rotterdam criteria which require two of three cardinal features: 
Oligo- or anovulation, clinical and/or biochemical hyperandrogenism, 
and polycystic ovaries on ultrasound [4].
Although clomiphene citrate (CC) is still the first-line ovulation induction 
(OI) treatment, Aromatase inhibitors (letrozole) score over CC for the OI in 
anovulatory PCOS women in terms of avoiding adverse effects and lower 
risk of multiple pregnancies [5]. In a meta-analysis of 26 randomized 
controlled trial (RCTs), letrozole was found to enhance live birth and 
pregnancy rates in subfertile women with anovulatory PCOS, compared 
to CC [6]. Therefore, letrozole with its oral route of administration, safety 
profile, and effectiveness in OI and ovarian stimulation is an attractive 
option and can be considered the first-line option for induction of 
ovulation in PCOS women [7]. Gonadotropin therapy considered second-
line therapy in anovulatory PCOS women who fail to conceive on OI [8].
The luteal phase is defined as the period between the ovulation and 
pregnancy occurrence or the start of the new menstruation [9].
Luteal phase deficiency (LPD) is a clinical expression of Corpus Luteal 
deficiency results from different pathophysiological mechanisms, 
comprise abnormal follicular development, and secretory dysfunction 
and both interne lead to the inadequate transformation of the 
endometrium to secretory, resulting in defective implantation of the 
blastocyst and deficient embryonic development [10].
LPD and PCOS are independent disorders, but they share common 
pathophysiological profiles. Many factors associated with PCOS, such as 
hyperinsulinemia, elevated antimullerian hormone levels, and impaired 
angiogenesis are also involved in the pathophysiology of LPD. Given 
the importance of CL function for the achievement and maintenance of 
pregnancy, LPD could be another possible factor involved in infertility 
observed in women with PCOS [11]. On the other hand, OI with the change in 
endocrine metabolism has negative effect on the luteal phase function [9]; 
controlled ovarian stimulation using gonadotropins negatively affects LH 
secretion that leads to premature luteolysis, decrease LH concentration 
and progesterone level, and shortened luteal phase, leading to improper 
implantation and decreased pregnancy rates [12]. Progesterone, in general, 
is the most commonly prescribed drug used in PCOS [13].
The objective of the current study was to assess the effect of 
progesterone as luteal phase support (LPS) on pregnancy rates 
in infertile PCOS patients who used letrozole alone or letrozole 
gonadotropin combination regime as a method of OI.
METHODS
A prospective randomized clinical study conducted in the infertility 
clinic - Al-Yarmouk Teaching Hospital in Baghdad/Iraq from June 2016 
to January 2018 after approval of the ethical and scientific committee of 
the obstetrics and gynecology department.
Unovulatory infertile women with PCOS between 20 and 35 years of age 
had been enrolled in the study after taking informed written consent 
from them. Modified Rotterdam criteria had been used to diagnose 
the PCOS. Thyroid dysfunction, hyperprolactinemia, and other causes 
of hyperandrogenism had been excluded. All participants had normal 
hysterosalpingography, and their partner had a normal seminal fluid 
analysis.
A total of 149 infertile polycystic ovary women who achieved ovulation 
using letrozole alone or letrozole with gonadotropin as OI protocol 
enrolled, a woman who failed to show a response to both regimes were 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i9.27047
Research Article
322
Asian J Pharm Clin Res, Vol 11, Issue 9, 2018, 321-324
 Alizzi 
excluded from the study. Accordingly, the study group divided into two: 
Group A (letrozole group, no=99) and Group B (letrozole gonadotropin 
group, no=50).
All the participant start treatment on 2nd or 3rd day cycle once baseline 
transvaginal ultrasound is done and no ovarian cyst was seen.
Group A women (no=99) received 5mg letrozole from day 2 or 3 of the 
cycle and followed up by ultrasound till the time of ovulation when 
the leading follicle ≥17, then ovulation triggered by hCG (ovidrel). At 
that time, the 100 women were re-randomized into two subgroups, 
Group A - one (no=49) who continue without LPS till 14 days after 
triggering when PT with or without ultrasound was done to confirm 
biochemical and or clinical pregnancy. The second subgroup A - two 
(no=50) they continue on LPS by oral progesterone (dydrogesterone 
10 mg twice daily) starting on the day after hCG triggering and continue 
daily for 14 days when pregnancy test with or without ultrasound done 
to confirm biochemical and or clinical pregnancy.
Group B women (no=50) received letrozole 5mg from day 2 or 3 of the 
cycle for 5 days and reassessed by ultrasound, if no response (no follicle 
≥10 mm) and recombinant gonadotropin FSH (Gonal F) were added for 
3–5 days (3–5 ampoules 75 IU) with meticulous ultrasound monitoring 
until one follicle at least, and not more than two, ≥17 mm achieved then 
triggering by hCG did (ovidrel). The women then after re-randomized 
again into two subgroups; Group B - one (no=25) who continue without 
LPS until 14 days after triggering when PT with or without ultrasound 
was done to confirm biochemical and or clinical pregnancy. The second 
subgroup B - two (no=25) they continue on LPS by oral progesterone 
(dydrogesterone 10 mg twice daily) the day after hCG triggering and 
continue for 14 days when pregnancy test with or without ultrasound 
done to confirm biochemical and or clinical pregnancy.
The protocol used for participant women in each group was repeated 
for 3 cycles unless biochemical or clinical pregnancy happened which it 
was the primary outcome measure.
Statistical analysis
SPSS 20.0.0, GraphPad Prism 7.0 software package used to make 
the statistical analysis, p-value considered when appropriate to be 
significant if <0.05.
RESULTS
Mean age of all patients was 26.7±2.4 years, with mean body mass 
index (BMI) 26.2±1.4, 65.1% was null parity with a mean duration of 
infertility 21.8±7.1 months, as illustrated in Table 1.
BMI, parity, and duration of infertility were not statistically significant 
among the different groups, while there was a statistical difference in 
the mean age between patients receiving letrozole with luteal support 
compared to letrozole with gonadotropin without LPS, as illustrated in 
Table 2.
There was no significant difference in the size of the dominant follicle 
between patients receiving letrozole only and the patient receiving 
letrozole with LPS. There was also no significant difference between 
patients on letrozole gonadotropin alone and patients receiving 
letrozole gonadotropin with LPS. On the contrary, patients receiving 
gonadotropin with or without LPS had significantly higher follicle size 
compared to their respective group that on letrozole only. The number 
of dominant follicles was significantly higher in patients receiving 
gonadotropin. There was no significant difference in the endometrial 
thickness and number of cycles among the different groups, there 
was no significant difference in the rate of positive pregnancy and US 
findings (GS with or without fetal pole and positive fetal heart) between 
the groups (although the rate of positive PT is higher for those on LPS) 
as illustrated in Table 3.
Patients receiving LPS achieve nonsignificantly higher rate of positive 
pregnancy test compared to letrozole alone or letrozole gonadotropin 
without LPS, as illustrated in Table 4.
After adjustment of possible confounders; patients receiving letrozole 
with gonadotropin with LPS had significantly correlated with a 
successful pregnancy test, while patients receiving letrozole with 
LPS had non-significantly correlated with positive PT, all these in 
comparison to patients receiving letrozole only without LPS, parity 
significantly correlated with positive PT, as illustrated in Table 5.
DISCUSSION
The benefit of progesterone for LPS in in vitro fertilization (IVF) cycles 
has been proved beyond doubt, but there is little agreement about the 
use of LPS following OI [14].
Since most of the patients with anovulatory infertility are treated with 
either CC or letrozole as a first line, it is vital to recognize women who 
may preferentially benefit from LPS before moving to more invasive 
assisted reproductive technologies. Patients with PCOS are one group 
that may benefit from progesterone supplementation [15].
Few studies were done to evaluate LPS in OI cycles using aromatase 
inhibitors.
In our study, two group had been taken; Group A includes 99 women 
used letrozole alone as OI, 49 of them did not use p as LPS, and 50 of 
them use progesterone as LPS; patient received LPS achieve an non-
significant higher rate of positive biochemical and clinical pregnancy 
compared to letrozole without LPS. The lack of statistical significance in 
our study may be due to small sample size and cycle numbers.
Our study results go with Montville et al. study which concluded 
that patients with PCOS who used letrozole for OI had higher clinical 
pregnancy rates when using progesterone support and strongly 
recommend it use [16].
The second group (Group B) included 50 women, 25 of then received 
letrozole with gonadotropins without LPS, and 25 of them received 
the same combination OI regime but with LPS. Women received LPS 
achieve a non-significant higher rate of positive biochemical and 
clinical pregnancy compared to women not using it. After adjustment 
of possible confounders; patients receiving letrozole with gonadotropin 
with LPS had significantly correlated with a successful pregnancy test.
Our study results go with Foroozanfard et al. results which showed 
LPS cycle was associated with a 10% higher pregnancy rate than cycles 
without, although this difference did not reach statistically significant, 
and they ended up with conclusion that administration of vaginal 
progesterone for LPS may improve the pregnancy rate in women with 
PCOS using letrozole or CC in combination with HMG for OI [17].
Our study was also in agreement with Yazici et al. who study the role 
of LPS on gonadotropin OI cycles in patients with PCOS and end up in 
conclusion that there might be a clinical benefit of luteal progesterone 
supplementation on OI/intrauterine insemination (IUI) cycles for 
Table 1: Basic characteristics of the patients
Variables Value
Number 149
Age (years), mean±SD (range) 26.7±2.4 (21.0–33.0)
BMI (kg/m2), mean±SD (range) 26.2±1.4 (18.0–29.0)
Parity, no. (%)
Null parity 97 (65.1)
Prime parity 44 (29.5)
Second parity 8 (5.4)
Duration of infertility (months), 
mean±SD (range)
21.8±7.1 (12.0–48.0)
SD: Standard deviation, BMI: Body mass index
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women with PCOS, although the results again did not reach a statistically 
significant [18].
Hill et al. did a systematic review and meta-analysis on Progesterone 
as a luteal support after OI but with IUI and end up in a conclusion that 
LPS may be of benefit to women undergoing OI with gonadotropins in 
IUI cycles but LPS did not show benefit in patients undergoing OI with 
CC; this difference might be due to differences in the endogenous luteal 
phase function depending on the method of OI [19].
Good clinical practice recommendations on the treatment of infertility 
in patients from India with PCOS recommended the administration of 
LPS in subfertile PCOS women undergoing OI [20].
In terms of route of administration, progesterone used as LPS in our 
study was oral Dydrogesterone (10 mg twice daily). This route of use 
in the study was supported by systematic review and meta-analysis of 
RCT done by Barbosa et al. who ended up in a conclusion that the use of 
oral dydrogesterone seems to be as effective as vaginal progesterone for 
LPS in ART cycles and appears to be better tolerated [21]; furthermore, 
oral route efficacy confirmed in IVF by Phase III-RCT that compares the 
efficacy, safety, and tolerability of oral dydrogesterone versus micronized 
vaginal progesterone for LPS [22]. Similar reports on equivalent efficacy 
were documented from RCTs in Iran and India [23,24].
CONCLUSION
Our study shows that administration of progesterone as LPS in infertile 
PCOS women using letrozole alone or with gonadotropins may improve 
pregnancy rate and its value is more pronounce in gonadotropin OI regimes.
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